Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
Date:2/27/2012

nses increased $19.9 million, or 242%, to $28.1 million for the three months ended December 31, 2011, from $8.2 million for the three months ended December 31, 2010. The higher expenses for the three months ended December 31, 2011 were primarily due to increased selling and marketing expenses associated with the full commercial launch of KRYSTEXXA.

Interest expense on the Company's convertible notes was $4.3 million for the three months ended December 31, 2011.

Conference Call and WebcastThe Company will host a live conference call and webcast beginning at 9:00 a.m. Eastern Time on February 27, 2012 to discuss these results and to answer questions. To participate by telephone, please dial:Domestic:

866-393-1565International:

253-237-1151Conference ID:

49538226The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on February 27, 2012 through 12:00 a.m. Eastern Time on March 7, 2012 by dialing:

Domestic:

855-859-2056International:

404-537-3406Conference ID:

49538226ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign paten
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
2. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
4. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
5. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
6. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
7. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
8. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
10. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a ... commercialization of prescription ophthalmic pharmaceuticals, announced today that it ... Growth Capital, Inc. (NYSE: HTGC ) (Hercules). ... the Loan and Security Agreement that Alimera,s subsidiary in ... Limited, entered into with Hercules in April of this ...
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... DIEGO, June 7, 2011 Tocagen Inc. ... high grade glioma, such as those with glioblastoma multiforme ... Toca 511. The multicenter, open-label study is ... of Toca 511 administered intratumorally followed by cycles of ...
... 2011 Topaz Pharmaceuticals Inc., a privately held specialty ... Drug Administration (FDA) accepted for filing the New Drug ... as a treatment for head lice infestations in children ... transition of the Company from the development phase as ...
Cached Medicine Technology:Tocagen's First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... computer tomography (CT) scans, imaging plays an important ... high-quality images often requires advanced technology and expertise, ... launches its preparatory phase today, aims to provide ... imaging technologies at all levels of biological and ...
... News) -- A problem in the lining of blood vessels ... according to a new study. The condition, called endothelial ... the layer of cells that line blood vessels. Nitric oxide ... improves blood flow and the delivery of oxygen and nutrients ...
... today at the annual meeting of the Radiological Society ... ionizing radiation from imaging procedures and efforts under way ... on the risks and benefits of medical imaging. ... chairman of the Department of Diagnostic Radiology at Yale ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- ... new study contends. The study included nearly 600 ... disorder that causes severe pain and diarrhea. The ... the study and 19 percent of them were found ...
... A U.S. Food and Drug Administration advisory committee on Wednesday ... prostate cancer, the third-highest cancer killer of men. ... of Merck,s Proscar outweighed its benefits, according to the ... voted 14-2, with two abstentions, against GlaxoSmithKline,s Avodart. Both drugs ...
... Ore. Young women veterans are nearly three times ... new research published by researchers at Portland State University ... The paper, "Self-Inflicted Deaths Among Women With U.S. ... 2010 issue of Psychiatric Services , a journal ...
Cached Medicine News:Health News:Better imaging from bench to bedside 2Health News:New Piece of Alzheimer's Puzzle Identified 2Health News:Expert panel addresses safety in medical imaging 2Health News:Expert panel addresses safety in medical imaging 3Health News:Study Suggests Link Between Crohn's Disease and PTSD 2Health News:FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer 2Health News:Suicide rate among young women veterans more than twice that of civilians 2
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: